中国肿瘤生物治疗杂志2012，Vol.19Issue(4)：414-420,7.DOI:10.3872/j.issn.1007-385X.2012.04.013
多肽负载DC联合CIK治疗激素难治性前列腺癌的疗效
Efficacy of polypeptide-loaded dendritic cells in combination with cytokine-induced killer cells on hormone refractory prostate cancer
摘要
Abstract
Objective; To investigate the efficacy of polypeptide-loaded dendritic cells (DCs) in combination with cy-tokine-induced killer cells (CIKs) against hormone refractory metastatic prostate cancer ( HRPC ) patients. Methods: Twenty-six HLA-A2 + patients with HRPC were enrolled from the Department of Chinese Traditional and Western Medicine of the Wuxi No. 4 People' s Hospital. Peripheral blood mononuclear cells ( PBMCs) were separated, and the adherent cells were induced into DCs by GM-CSF and IL-4. Then DCs were loaded with three peptides ( prostate specific antigen, PSA; prostatic acid phosphatase, PAP; prostate specific membrane antigen, PSMA) to prepare DC vaccine and were injected intracutaneously. The un-adherent cells of PBMCs were induced into CIK by IFN-7, IL-2, CD3 monoclonal antibody and IL-1, and were injected intravenously. Delayed type hypersensitivity ( DTH) was detected one week after treatment , and cytokine and PSA in serum were determined before and after treatment. The short-term efficacy was evaluated 4 weeks after treatment. Results; DC-CIK therapy was well tolerated in 26 HRPC patients. The serum IL-2, IL-12, and IFN-γ levels after therapy were significantly increased ( increased 65. 07% , 67. 69% and 125. 38% , P <0. 05 or P <0. 01) , while TNF-α and IL-10 levels were unchanged. The positive rate of DTH was 43.5% (10/23). The proportion of CD8+IFNγ+ cells after therapy was significantly increased ( [8.95 ±2. 74] % vs [0. 39 ±0. 15]% , P<0.01). A decrease of PSA ( 13% to 66% ) was observed in 8 of 26 patients. The short-term efficacy of 26 HRPC patients was evaluated, with 3 PR, 4 PD, and 19 SD after treatment, and no severe adverse reaction was observed. Conclusion: The poly-peptide-loaded DC in combination with CIK therapy can elicit specific immune responses in HRPC patients, and induce type I cytokine secretion with well short-term clinical efficacy, indicating that DC-CIK therapy is a safe treatment for HRPC.关键词
树突状细胞/细胞因子诱导的杀伤细胞/激素难治性前列腺癌/PSA/PAP/PSMAKey words
dendritic cell/ cytokine-induced killer cell/ hormone refractory metastatic prostate cancer/ PSA/ PAP/ PSMA分类
医药卫生引用本文复制引用
章烨,朱寿兴,申小苏,朱为民,马素娟,时宏珍,史央,朱晨瑶,李蔚..多肽负载DC联合CIK治疗激素难治性前列腺癌的疗效[J].中国肿瘤生物治疗杂志,2012,19(4):414-420,7.基金项目
无锡市科技局指导性计划项目资助. （）
